New

Turn ETF ideas into real portfolios. Try the builder now →

Advertisement
Advertisement

ALPS Medical Breakthroughs ETF

This ETF provides exposure to Mid and Small-Cap US Equities

SBIO performance and flow charts

Last update 9/10/2026 at 1:30 PM
Live
Closed
Last price
$63.80
-$1.40 (-2.14%) Yesterday

Performance

-4.0-2.00.02.04.06.0%Aug 10Aug 17Aug 24Aug 31Sep 8

Flows

0 M5 M10 M15 M20 M25 M30 M35 M
1 day price range
$63.69
$64.54
52 week price range
$35.69
$70.68
1W perf
-5.20%
YTD perf
+24.90%
YTD flows
+$75M
AuM
$235M
E/R
0.5%
TTM yield
-
Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

Historic performance and flows

Data as of September 10, 2026
1M3MYTD1Y3Y5Y
Perf.-4.73%+26.53%+24.90%+75.78%+121.32%+43.40%
Flows+$31M+$51M+$75M+$84M+$56M+$17M
Data as of September 10, 2026

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Characteristics

The ALPS Medical Breakthroughs ETF is built to track the S-Network Medical Breakthroughs Index NTR - USD. This ETF provides physical exposure - by owning its shares you earn the return of the securities composing the index (as the ETF holds them directly). This share class generates a stream of income by distributing dividends.

Management strategyPassive
StrategyLong Only
ProviderALPS
N° of holdings104
Replication methodDirect (Physical)
Asset classEquity
Dividend policyDistributing
Trailing 12m distribution yield
Join for free
Inception dateDecember 30, 2014
ESGNo
TrackinsightTrackinsight

More data and info about SBIO on Trackinsight

Exposure

Data as of July 31, 2026

Diversification

42.78%

Total weight of top 15 holdings out of 104

Top 15 Holdings

Crinetics Pharmaceuticals, Inc.
4.75%
Apogee Therapeutics, Inc.
4.48%
CG Oncology, Inc.
3.39%
Xenon Pharmaceuticals, Inc.
3.26%
Dianthus Therapeutics, Inc.
3.15%
Oruka Therapeutics, Inc.
3.14%
Travere Therapeutics, Inc.
2.8%
Definium Therapeutics, Inc.
2.56%
ACADIA Pharmaceuticals, Inc.
2.39%
Veradermics, Inc.
2.36%
Dyne Therapeutics, Inc.
2.25%
Edgewise Therapeutics, Inc.
2.23%
Relay Therapeutics, Inc.
2.22%
Denali Therapeutics, Inc.
1.97%
Structure Therapeutics, Inc.
1.84%

Sectors

Healthcare
100.02%
Other
-0.02%

Countries

USA
89.23%
Other
10.77%
Advertisement

Trading data

Last sale
9/10/2026 at 1:30 PM
$63.80
Previous close
$65.20
Consolidated volume
09/10/2026
Join for free
Average volume
30 days
Join for free
Average discount or premium
30 days
Join for free
Average Bid/Ask spread
30 days
Join for free

Volatility and drawdown

3M1Y3Y5Y
Volatility+32.19%+30.94%+31.10%+33.90%
Max drawdown
-9.65%-12.63%-42.12%-52.50%
Max drawdown duration
22d60d331d1479d
Time to recover
N/A11d184d757d

Replication quality

Data as of August 31, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free
Tracking error
Join for free
Tracking difference
Join for free
1 year cumulative return difference
Best
Join for free
Worst
Join for free
daily return difference
Average
Join for free
Worst
Join for free
Advertisement
Frequently asked questions about SBIO

What type of ETF is SBIO?

SBIO is a Passive ETF that provides exposure to Equity assets. It is managed by ALPS.

What index does SBIO track?

SBIO tracks the S-Network Medical Breakthroughs Index NTR - USD, aiming to replicate its performance through full replication.

What does SBIO invest in?

This ETF provides exposure to Mid and Small-Cap US Equities. It is part of the segment: Tomorrow's Treatments.

What is the expense ratio of SBIO?

The total expense ratio (TER) of SBIO is 0.5%, representing the annual fee charged by the fund manager.

When was SBIO launched?

SBIO was launched on December 30, 2014, marking its entry into the ETF market.

Who is the issuer of SBIO?

SBIO is issued by ALPS.

What is the AUM of SBIO?

As of September 10, 2026, SBIO manages $234.69 M, reflecting the total assets held in the fund.

How has SBIO performed recently?

As of September 10, 2026, SBIO delivered a return of -4.73% over the past month (1M performance), 26.53% over the past three months (3M), and 24.9% year-to-date (YTD).

What are the recent fund flows for SBIO?

As of September 10, 2026, SBIO has seen net flows of +$31M in the past month (1M flow) and +$75M year-to-date (YTD).

How many holdings are in SBIO

As of July 31, 2026, SBIO holds 104 securities in its portfolio. This level of diversification can influence the fund’s risk profile and exposure to individual assets.

How diversified is SBIO?

As of July 31, 2026, SBIO holds 104 securities, with 42.78% of its assets concentrated in its top 15 holdings.

What are the top holdings of SBIO?

As of July 31, 2026, SBIO holds a portfolio of 104 underlyings, with its largest positions including Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc.. These top holdings play a significant role in shaping the fund’s performance and exposure.

What countries or regions does SBIO invest in?

As of July 31, 2026, SBIO has its largest geographic exposures in USA.

What sectors or themes does SBIO focus on?

As of July 31, 2026, SBIO is primarily exposed to Healthcare.

The ETF Institute® is now affiliated with ETF Central

The CETF certification is the only FINRA listed professional designation focused on ETFs.

ETF Institute
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides
Advertisement

Recent educational content

Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 8, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 9, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs August 31, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 1, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs August 24, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · August 24, 2026
What's the Fund | Ocean Park Diversified Income ETF (DUKZ)

What’sTheFund

What's the Fund | Ocean Park Diversified Income ETF (DUKZ)

James St Aubin, Chief Investment Officer at Ocean Park Asset Management, discuss the DUKZ ETF, exposing investors to the whole spectrum of asset classes in the fixed income markets, through their rules-based process.

NYSE logo
By NYSE · August 18, 2026

Browse all educational columns

Advertisement
ETF INVESTOR TOOLS

Build and Analyze Your ETF Portfolio Like a Pro

Create your own ETF portfolio in minutes and instantly see allocations, exposures, performance, and risk. Visualize diversification across asset classes, regions, and sectors. Stress-test ideas, compare benchmarks, and refine your strategy with professional-grade analytics.

Portfolio Builder